Uppsala, Sweden

David Andreas Tilly

USPTO Granted Patents = 4 

 

Average Co-Inventor Count = 4.9

ph-index = 1

Forward Citations = 2(Granted Patents)


Company Filing History:


Years Active: 2021-2025

Loading Chart...
Loading Chart...
4 patents (USPTO):Explore Patents

Title: David Andreas Tilly: Innovator in Radiotherapy Technology

Introduction

David Andreas Tilly is a prominent inventor based in Uppsala, Sweden. He has made significant contributions to the field of radiotherapy, holding a total of 4 patents. His work focuses on developing innovative techniques that enhance the precision and effectiveness of cancer treatment.

Latest Patents

Among his latest patents is the "Adaptive Dose Accumulation Algorithm." This invention provides techniques for adjusting radiotherapy treatment for a patient in real time. The process involves obtaining images of the patient during treatment, generating patient motion information, and computing the dose delivered with varying levels of accuracy. Another notable patent is "Geometry-Based Real-Time Adaptive Radiotherapy." This invention includes methods for retrieving a reference plan, identifying target volumes, and updating treatment parameters based on patient deformation during treatment.

Career Highlights

David Andreas Tilly is currently associated with Elekta AB, a company renowned for its advancements in radiotherapy technology. His work at Elekta has positioned him as a key player in the development of innovative solutions that improve patient outcomes in cancer treatment.

Collaborations

Some of his notable coworkers include Peter Kimstrand and Nina Terese Tilly. Their collaborative efforts contribute to the ongoing advancements in radiotherapy techniques and technologies.

Conclusion

David Andreas Tilly's contributions to radiotherapy through his patents and work at Elekta AB highlight his commitment to improving cancer treatment. His innovative approaches continue to shape the future of medical technology.

This text is generated by artificial intelligence and may not be accurate.
Please report any incorrect information to support@idiyas.com
Loading…